Intramolecular Hydrogen Bonds for Brain-Penetrant Therapeutics

by Corin Wagen · Aug 6, 2024

The blood–brain barrier (BBB) is a semi-permeable membrane that separates the central nervous system (CNS) from the bloodstream. This serves to protect the CNS from toxins and other environmental harms, but also makes it difficult to deliver therapeutics to the CNS: it has been estimated that over 98% of small-molecule drugs are not BBB-penetrant.

Modifications to Increase BBB Penetrance

Extensive empirical studies have found a number of physicochemical properties which typically predict whether a given molecule will be BBB penetrant or not. A study of top CNS-active drugs found that virtually all of them had a low molecular weight, low total polar surface area, high lipophilicity, and—perhaps most crucially—at most one hydrogen-bond donor. These constraints make it extremely difficult to develop potent CNS therapeutics, as polar groups and hydrogen-bond donors are often key design elements that lead to high binding affinity and low IC50 values.

To help make potent drugs more CNS-penetrant without unduly sacrificing potency, hydrogen-bond donors can be "masked" by adding a weak internal hydrogen-bond acceptor to form an intramolecular hydrogen bond. This often increases the permeability of the molecule while maintaining binding affinity: the intramolecular hydrogen bond is robust enough to allow molecules to diffuse through the BBB, but not so strong that the molecule cannot adopt the preferred binding pose and engage a hydrogen-bond acceptor on the target.

Identifying a BBB-Penetrant IP6K1 Inhibitor

A recent paper from Barrow and co-workers at Johns Hopkins used this strategy to design an IP6K1 inhibitor capable of passing through the blood–brain barrier. IP6K1 is a kinase that's key to the inositol phosphate signaling pathway and has attracted considerable interest as a target for many different indications. Sadly, existing IP6K1 inhibitors all contain key carboxylic acids, which are ionized at physiological pH and thus prevent BBB penetration.

Replacing the carboxylic acid with an amide doesn't improve BBB penetrance

Replacing the carboxylic acid with an amide doesn't improve BBB penetrance

The authors tried a ton of different modifications to turn their existing IP6K1 inhibitor into a CNS-compatible IP6K1 inhibitor. Replacing the carboxylic acid with a carboxamide residue (which is neutral at pH 7.4) preserved most of the potency but led to even lower BBB penetrance, which the authors attribute to the additional hydrogen-bond donor moiety introduced.

Adding ortho-fluorine atoms dramatically improves permeability

Adding ortho-fluorine atoms dramatically improves permeability

The authors went on to explore introduction of an internal hydrogen bond to mask the carboxamide: while introducing a pyridine group improved permeability at the expense of potency, adding an ortho-fluorine preserved potency and dramatically increased BBB permeability for both the acid and the amide. Ultimately, they chose to move forward with the amide and found that it had a 173x greater brain/plasma ratio than the starting compound and good pharmacokinetic properties.

Modeling Intramolecular Hydrogen Bonding

This paper serves as a great case study of how introducing intramolecular hydrogen bonding can improve BBB penetrance. To understand the effects described in this paper in more detail, we can use Rowan to quickly compute the potential energy surface for the hydrogen-bond acceptor. Here's a comparison of scans for the parent phenyl compound, the pyridyl compound, and the ortho-fluoro compound.

A comparison of different hydrogen-bond acceptors; click to view the full interactive page

We can see that in the absence of a hydrogen-bond acceptor the s-cis carboxylic acid conformation is strongly preferred. Addition of a strong hydrogen-bond acceptor (pyridine) shifts the ground state towards the s-trans carboxylic acid conformation, consistent with the increased BBB penetrance and decreased potency observed. The ortho-fluorine serves as a weak hydrogen-bond acceptor, making the intramolecular hydrogen-bonded conformation energetically accessible but maintaining the same ground state.

These calculations suggest that there's a "Goldilocks" zone of hydrogen-bond-acceptor strength for intramolecular bonds: acceptors need to be strong enough to mask hydrogen-bond donors in a membrane environment, but not so strong that they compete in the binding site. This chameleonicity has been remarked upon as a key feature of macrocycles, enabling them to change their physicochemical properties in an environment-specific manner.

Prospective Design of BBB-Penetrant Therapeutics

This study, while retrospective, illustrates how calculations can be used for the rational design of CNS-compatible small molecules. The calculations run here took only minutes through Rowan's cloud platform, and the figures were generated automatically through Rowan's molecule viewer.

Rowan provides an optimized workflow for running scans that's ideally suited to running calculations like the ones shown here, where a quick estimate of the relative energies of two states is needed. Rowan also contains cutting-edge machine-learned interatomic potentials that can generate torsional profiles with chemical accuracy in a fraction of the time demanded by traditional quantum chemical methods, meaning that your scans can run in minutes instead of days.

Banner background image

What to Read Next

Studying Scaling in Electron-Affinity Predictions

Studying Scaling in Electron-Affinity Predictions

Testing low-cost computational methods to see if they get the expected scaling effects right.
Sep 10, 2025 · Corin Wagen
Open-Source Projects We Wish Existed

Open-Source Projects We Wish Existed

The lacunæ we've identified in computational chemistry and suggestions for future work.
Sep 9, 2025 · Corin Wagen, Jonathon Vandezande, and Ari Wagen
How to Make a Great Open-Source Scientific Project

How to Make a Great Open-Source Scientific Project

Guidelines for building great open-source scientific-software projects.
Sep 9, 2025 · Jonathon Vandezande
ML Models for Aqueous Solubility, NNP-Predicted Redox Potentials, and More

ML Models for Aqueous Solubility, NNP-Predicted Redox Potentials, and More

the promise & peril of solubility prediction; our approach and models; pH-dependent solubility; testing NNPs for redox potentials; benchmarking opt. methods + NNPs; an FSM case study; intern farewell
Sep 5, 2025 · Eli Mann, Corin Wagen, and Ari Wagen
Machine-Learning Methods for pH-Dependent Aqueous-Solubility Prediction

Machine-Learning Methods for pH-Dependent Aqueous-Solubility Prediction

Prediction of aqueous solubility for unseen organic molecules remains an outstanding and important challenge in computational drug design.
Sep 5, 2025 · Elias L. Mann, Corin C. Wagen
What Isaiah and Sawyer Learned This Summer

What Isaiah and Sawyer Learned This Summer

Reflections from our other two interns on their time at Rowan and what they learned.
Sep 5, 2025 · Isaiah Sippel and Sawyer VanZanten
Benchmarking OMol25-Trained Models on Experimental Reduction-Potential and Electron-Affinity Data

Benchmarking OMol25-Trained Models on Experimental Reduction-Potential and Electron-Affinity Data

We evaluate the ability of neural network potentials (NNPs) trained on OMol25 to predict experimental reduction-potential and electron-affinity values for a variety of main-group and organometallic species.
Sep 4, 2025 · Sawyer VanZanten, Corin C. Wagen
Which Optimizer Should You Use With NNPs?

Which Optimizer Should You Use With NNPs?

The results of optimizing 25 drug-like molecules with each combination of four optimizers (Sella, geomeTRIC, and ASE's implementations of FIRE and L-BFGS) and four NNPs (OrbMol, OMol25's eSEN Conserving Small, AIMNet2, and Egret-1) & GFN2-xTB.
Sep 4, 2025 · Ari Wagen and Corin Wagen
Double-Ended TS Search and the Invisible Work of Computer-Assisted Drug Design

Double-Ended TS Search and the Invisible Work of Computer-Assisted Drug Design

finding transition states; the freezing-string method; using Rowan to find cool transition states; discussing drug design
Sep 3, 2025 · Jonathon Vandezande, Ari Wagen, Spencer Schneider, and Corin Wagen
The Invisible Work of Computer-Assisted Drug Design

The Invisible Work of Computer-Assisted Drug Design

Everything that happens before the actual designing of drugs, and how Rowan tries to help.
Aug 28, 2025 · Corin Wagen